I
Ira Chalikonda
Researcher at Merck & Co.
Publications - 7
Citations - 635
Ira Chalikonda is an academic researcher from Merck & Co.. The author has contributed to research in topics: ELISPOT & Booster dose. The author has an hindex of 7, co-authored 7 publications receiving 606 citations. Previous affiliations of Ira Chalikonda include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Decline in Varicella-Zoster Virus (VZV)–Specific Cell-Mediated Immunity with Increasing Age and Boosting with a High-Dose VZV Vaccine
Myron J. Levin,Jeffrey G. Smith,Robin M. Kaufhold,Debra Barber,Anthony R. Hayward,Christina Y. Chan,Ivan S. F. Chan,David J. J. Li,William Wang,Paul M. Keller,Alan Shaw,Jeffrey L. Silber,Katia Schlienger,Ira Chalikonda,S. J. R. Vessey,Michael J. Caulfield +15 more
TL;DR: A live attenuated VZV vaccine is safe and immunogenic in an elderly population, and the vaccine-induced immunity may be monitored by the IFN-gamma ELISPOT assay, which had greater sensitivity and a wider dynamic range.
Journal ArticleDOI
Diurnal variation of the human adipose transcriptome and the link to metabolic disease
Andrey Loboda,Walter K. Kraft,Bernard Fine,Jeffrey I. Joseph,Michael Nebozhyn,Chunsheng Zhang,Yudong He,Xia Yang,Christopher M. Wright,Mark Morris,Ira Chalikonda,Mark D. Ferguson,Valur Emilsson,Amy Leonardson,John Lamb,Hongyue Dai,Eric E. Schadt,Howard E. Greenberg,Pek Yee Lum +18 more
TL;DR: Diurnal rhythm plays an important role in the physiology and regulation of energy metabolism in the adipose tissue and should be considered in the selection of novel targets for the treatment of obesity and other metabolic disorders.
Journal ArticleDOI
Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells.
TL;DR: The results suggest that protein kinase C mediated phosphorylation stimulates the drug transport activity of P-glycoprotein in drug-resistant human KB carcinoma cells.
Journal ArticleDOI
Immunoprecipitation and Virus Neutralization Assays Demonstrate Qualitative Differences between Protective Antibody Responses to Inactivated Hepatitis A Vaccine and Passive Immunization with Immune Globulin
Stanley M. Lemon,Paula C. Murphy,Philip J. Provost,Ira Chalikonda,Joseph P. Davide,Timothy L. Schofield,David R. Nalin,John A. Lewis +7 more
TL;DR: These data establish serologic correlates of protection against disease and show that RIPA is most sensitive for detection of early vaccine-induced antibody in children 4 weeks after a dose of inactivated hepatitis A vaccine.
Journal ArticleDOI
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age
Joost N. Vermeulen,Joep M. A. Lange,Stephen K. Tyring,Patrick H. Peters,Margaret Nunez,Gregory A. Poland,Myron J. Levin,Carrie Freeman,Ira Chalikonda,Jianjun Li,Jeffrey G. Smith,Michael J. Caulfield,Jon E. Stek,Ivan S. F. Chan,Rupert Vessey,Florian Schödel,Paula W. Annunziato,Katia Schlienger,Jeffrey L. Silber +18 more
TL;DR: A second dose of zoster vaccine was generally safe, but did not boost VZV-specific immunity beyond levels achieved postdose 1, and ZV was generally well-tolerated and immunogenic in adults ≥60 years old.